Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Guia Ladrera"'
Autor:
Lin Wu, David S. Shames, Barbara Klughammer, Matt Truman, Julie Tsai, Wei Wen, Benjamin Margono, Fatima Fuerte, Caicun Zhou, Yunzhong Zhu, Meilin Liao, Vichien Srimuninnimit, Sumitra Thongprasert, Guia Ladrera, Jennifer Sandoval-Tan, Virote Sriuranpong, Chong-Jen Yu, Jin Soo Lee, Yi-Long Wu, Tony Mok
Supplementary Figure 1. (A) PFS in the cfDNA mut+ subgroup (B) OS in the cfDNA mut+ subgroup (C) PFS in the cfDNA mut+ subgroup (patients with no tissue result) (D) OS in the cfDNA mut+ subgroup (patients with no tissue result) (E) PFS in the cfDNA m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::99267496a9f0d581dbea95dfc1b10c8e
https://doi.org/10.1158/1078-0432.22459443.v1
https://doi.org/10.1158/1078-0432.22459443.v1
Autor:
Lin Wu, David S. Shames, Barbara Klughammer, Matt Truman, Julie Tsai, Wei Wen, Benjamin Margono, Fatima Fuerte, Caicun Zhou, Yunzhong Zhu, Meilin Liao, Vichien Srimuninnimit, Sumitra Thongprasert, Guia Ladrera, Jennifer Sandoval-Tan, Virote Sriuranpong, Chong-Jen Yu, Jin Soo Lee, Yi-Long Wu, Tony Mok
Supplementary Tables 1-4. Supplementary Table 1. Concordance, sensitivity, specificity, positive and negative predictive values of tissue and cfDNA tests (n=238) by EGFR mutation type Supplementary Table 2: EGFR mutation type Supplementary Table 3: E
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f4987cacd97c4d34db3f643a69c08b68
https://doi.org/10.1158/1078-0432.22459440
https://doi.org/10.1158/1078-0432.22459440
Autor:
Lin Wu, David S. Shames, Barbara Klughammer, Matt Truman, Julie Tsai, Wei Wen, Benjamin Margono, Fatima Fuerte, Caicun Zhou, Yunzhong Zhu, Meilin Liao, Vichien Srimuninnimit, Sumitra Thongprasert, Guia Ladrera, Jennifer Sandoval-Tan, Virote Sriuranpong, Chong-Jen Yu, Jin Soo Lee, Yi-Long Wu, Tony Mok
Purpose: Blood-based circulating-free (cf) tumor DNA may be an alternative to tissue-based EGFR mutation testing in NSCLC. This exploratory analysis compares matched tumor and blood samples from the FASTACT-2 study.Experimental Design: Patients were
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9fd7c00c885259dc1fc67b73bb4dbefa
https://doi.org/10.1158/1078-0432.c.6524220
https://doi.org/10.1158/1078-0432.c.6524220
Autor:
Jie Wang, Kasan Seetalarom, Yi-Long Wu, Vichien Srimuninnimit, Chong-Jen Yu, Li Zhang, Gee-Chen Chang, Virote Sriuranpong, Matt Truman, Yan Sun, Tony Mok, Guia Ladrera, Elisna Syahruddin, Benjamin Margono, Meilin Liao, Hsingjin Eugene Liu, James Chung-Man Ho, Kate Jin, Caicun Zhou, Fatima Fuerte, Sumitra Thongprasert, Ilze Bara, Hongming Pan, Johan Kurnianda, Jennifer Sandoval-Tan, Jin Soo Lee, Ashley Cheng, Yunzhong Zhu, V. Lee, Xiaoping Qian, Yuh Min Chen
Publikováno v:
The Lancet Oncology. 14:777-786
Summary Background The results of FASTACT, a randomised, placebo-controlled, phase 2 study, showed that intercalated chemotherapy and erlotinib significantly prolonged progression-free survival (PFS) in patients with advanced non-small-cell lung canc
Autor:
Sumitra Thongprasert, Jin Soo Lee, Guia Ladrera, Pablo Perez-Moreno, Chong-Jen Yu, David S. Shames, Fatima Fuerte, Virote Sriuranpong, Yi-Long Wu, Matt Truman, Vichien Srimuninnimit, Jennifer Sandoval-Tan, Barbara Klughammer, Tony Mok
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 98
ObjectivesThe FASTACT-2 study of intercalated erlotinib with chemotherapy in Asian patients found that EGFR mutations were the main driver behind the significant progression-free survival (PFS) benefit noted in the overall population. Further explora
Autor:
Jennifer Sandoval-Tan, Barbara Klughammer, Sumitra Thongprasert, Matt Truman, Guia Ladrera, Wei Wen, Tony Mok, Julie Tsai, Jin Soo Lee, Virote Sriuranpong, Yi-Long Wu, David S. Shames, Lin Wu, Yunzhong Zhu, Benjamin Margono, Vichien Srimuninnimit, Chong-Jen Yu, Caicun Zhou, Meilin Liao, Fatima Fuerte
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 21(14)
Purpose: Blood-based circulating-free (cf) tumor DNA may be an alternative to tissue-based EGFR mutation testing in NSCLC. This exploratory analysis compares matched tumor and blood samples from the FASTACT-2 study. Experimental Design: Patients were
Autor:
Guia Ladrera, Sumitra Thongprasert, Y-L. Wu, Barbara Klughammer, C. Yu, L. J. Zhang, Tony Mok, J.S. Lee, Matt Truman, Vichien Srimuninnimit
Publikováno v:
ResearcherID
Background FASTACT-2 is a randomized, placebo-controlled, phase 3 study in first-line advanced NSCLC, which met its primary endpoint of significantly prolonged PFS with intercalated erlotinib and chemotherapy: median 7.6 vs 6.0 months; HR = 0.57; p M
Autor:
Yunzhong Zhu, Kate Jin, Vichien Srimuninnimit, Jin Soo Lee, Yi-Long Wu, Chong-Jen Yu, Virote Sriuranpong, Li Zhang, Caicun Zhou, Matt Truman, Guia Ladrera, Hongming Pan, Benjamin Margono, Meilin Liao, Yan Sun, Victor C. S. Lee, Sumitra Thongprasert, Jennifer Sandoval-Tan, Yuh Min Chen, Tony Mok
Publikováno v:
ResearcherID
7519^ Background: FASTACT, a randomized, phase 2 study in advanced NSCLC, found that intercalated erlotinib with 1st-line platinum-based chemotherapy (CT) significantly prolongs progression-free survival (PFS) (HR 0.47, p=0.0002) versus CT alone (Mok
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::63e0b874ca39a8fa4d64968902355c66
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=ORCID&SrcApp=OrcidOrg&DestLinkType=FullRecord&DestApp=WOS_CPL&KeyUT=WOS:000318009804295&KeyUID=WOS:000318009804295
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=ORCID&SrcApp=OrcidOrg&DestLinkType=FullRecord&DestApp=WOS_CPL&KeyUT=WOS:000318009804295&KeyUID=WOS:000318009804295